Rituximab cancer drug

Rituximab cancer drug

M625/1538 Rights Managed

Request low-res file

530 pixels on longest edge, unwatermarked

Request/Download high-res file

Uncompressed file size: 47.3MB

Downloadable file size: 1.9MB

Price image Pricing

Please login to use the price calculator


Restrictions: Editorial use only

Caption: Rituximab cancer drug. Bottle containing a liquid concentrate of the cancer drug rituximab, which is marketed as MabThera. Rituximab is a monoclonal antibody used to treat B cell non-Hodgkin's lymphoma and B cell leukaemia. B cells are a type of white blood cell. The antibody works by binding to CD20 receptors on the surface of the B cells, which flags them for destruction by the body's immune system. This clears the B cells, including the cancerous cells, from the blood, allowing them to be replaced with healthy cells produced by stem cells in the bone marrow. Rituximab may also be used to treat autoimmune diseases that result from the proliferation of B cells, to help prevent rejection of transplanted organs, and to treat rheumatoid arthritis.

Release details: Model release not required. Property release not required.

Keywords: 500mg, 50ml, arthritis, b cell leukaemia, bottle, cancer drug, cd20 receptor, chemotherapy, concentrate, drug, drugs, healthcare, label, leukemia, liquid, lymphoma, mabthera, medical, medicine, monoclonal antibody, non-hodgkin's lymphoma, oncology, one, pharmaceutic, pharmaceutical, phial, prescription drug, rheumatoid, rituximab, sealed, single, solution, still life, still-life, treatment, vial

Licence fees: A licence fee will be charged for any media (low or high resolution) used in your project.